BIOMAT Database Logo BIOMAT Database Logo

Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes. 1991

N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias

UI MeSH Term Description Entries
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015375 Receptors, Interleukin-2 Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN. IL-2 Receptors,Interleukin-2 Receptor,Interleukin-2 Receptors,Receptors, IL-2,Receptors, T-Cell Growth Factor,T-Cell Growth Factor Receptors,IL-2 Receptor,IL2 Receptor,IL2 Receptors,Interleukin 2 Receptor,Receptor, TCGF,T-Cell Growth Factor Receptor,TCGF Receptor,TCGF Receptors,IL 2 Receptor,IL 2 Receptors,Interleukin 2 Receptors,Receptor, IL-2,Receptor, IL2,Receptor, Interleukin 2,Receptor, Interleukin-2,Receptors, IL 2,Receptors, IL2,Receptors, Interleukin 2,Receptors, T Cell Growth Factor,Receptors, TCGF,T Cell Growth Factor Receptor,T Cell Growth Factor Receptors

Related Publications

N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased levels of soluble tumor necrosis factor receptors in patients with aplastic anemia and myelodysplastic syndrome.
December 2000, American journal of hematology,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.
October 1991, Cancer research,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Plasma soluble interleukin-2 receptors in patients with myelodysplastic syndromes.
December 1997, Leukemia & lymphoma,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased serum interleukin 6 levels in patients with myelodysplastic syndromes.
January 1992, Leukemia research,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients.
January 1991, Leukemia,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia.
September 1996, Obstetrics and gynecology,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased serum levels of soluble tumor necrosis factor a-receptors in patients undergoing partial liver resection.
January 1998, Hepato-gastroenterology,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor.
October 1998, Inflammation,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.
March 1990, British journal of cancer,
N Zoumbos, and A Symeonidis, and A Kourakli, and P Katevas, and P Matsouka, and M Perraki, and V Georgoulias
Increased serum levels of soluble tumor necrosis factor receptor-2 (sTNFR2) in patients with active toxoplasmic retinochoroiditis.
January 2012, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases,
Copied contents to your clipboard!